簡介：
Tobira Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat liver disease, human immunodeficiency virus, or HIV, fibrosis and inflammation. Our lead product candidate, cenicriviroc, or CVC, is a proprietary immunomodulator that can potentially be used to treat a number of disease states with high unmet medical need. We are developing CVC for nonalcoholic steatohepatitis, or NASH, for which we plan to begin a Phase 2 clinical trial in the second half of 2014. We also plan to advance CVC in a fixed-dose combination for HIV type 1, or HIV-1, infection through Phase 3 development and commercialization in collaboration with a strategic partner or with non-dilutive financing. CVC is a once-daily pill with well-established safety and tolerability in approximately 550 subjects dosed in completed Phase 1 and Phase 2 trials, including 115 HIV-infected subjects on treatment for up to 48 weeks.